Sana Biotechnology

91 articles about Sana Biotechnology

• Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

  5/8/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the first quarter 2023.

• Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

  5/8/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Nature Biotechnology has published a paper titled “Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.”

• Sana Biotechnology to Present at May 2023 Investor Conferences

  5/3/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in May.

• Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

  5/2/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA) today announced that six abstracts highlighting preclinical data from the fusogen platform have been accepted for presentation, including two oral presentations, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023 in Los Angeles, CA.

• Sana Biotechnology to Host Research & Development Day

  4/24/2023

  Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that management will host a Research & Development Day on Thursday, May 23, 2023 from 9:00 a.m. – 12:00 p.m. ET in New York, NY.

• Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

  4/19/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced data from four presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

• Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

  4/13/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Nature Communications has published a paper titled “Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice.”

• Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model

  4/12/2023

  Sana Biotechnology, Inc. announced that Science Translational Medicine has published a paper titled “Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice.”

• Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

  4/10/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointments of two senior leaders to its research and development organization, Douglas E. Williams, Ph.D., as President of Research and Development, and Gary Meininger, M.D., as Chief Medical Officer.

• Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

  3/16/2023

  Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

• Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting

  3/14/2023

  Sana Biotechnology, Inc. announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

• Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference

  3/1/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Cowen 43rd Annual Health Care Conference at 9:50 a.m. ET on Wednesday, March 8, 2023.

• Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference

  2/2/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Guggenheim Healthcare Talks 5th Annual Oncology Conference at 1:00 p.m. ET on Thursday, February 9, 2023.

• Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

  1/26/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a first-in-human study of SC291 in patients with various B-cell malignancies.

• Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Tuesday, January 10, 2023.

• Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting

  12/11/2022

  Sana Biotechnology, Inc. shared data in six presentations at the 64th American Society of Hematology Annual Meeting and Exposition, taking place from Saturday, December 10 to Tuesday, December 13, 2022 in New Orleans, LA, which highlighted further progress with key technologies supporting Sana’s ex vivo allogeneic CAR T cell programs and in vivo platform.

• Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization

  11/29/2022

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced a portfolio prioritization designed to optimize the development of programs at or nearing clinical development, continue investments in our core research platforms and innovation, and maintain a strong balance sheet with an expected cash runway into 2025.

• 

  Sana and BioLife Tout BioForest Region as Best Place to Work

  11/16/2022

  CEOs at Sana Biotechnology and BioLife Solutions explain how being based in the BioForest region helped them be voted one of BioSpace's best places to work in 2023.
• 

  Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers

  11/15/2022

  BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.

• Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category

  11/14/2022

  Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that it has been named the top place to work on the BioSpace 2023 Best Places to Work small employer list.